Scholarlink

Background <p>Higher intakes of ultra-processed food (UPF) and minimally processed food (MPF) are linked to increased and decreased cardiometabolic risks, respectively, though mechanisms underlying these associations remain less understood. We aimed to identify metabolomic signatures associated with UPF and MPF intakes, examine their prospective associations with cardiovascular disease (CVD) and type 2 diabetes (T2D), and quantify their mediation of processing-disease associations.</p> Methods <p>In the Whitehall II cohort, UPF and MPF intakes in 6010 participants were derived using the Nova classification from 127-item food frequency questionnaires administered at phases 3 and 5 (1991–1994, 1997–1999), averaged across phases. Fasting plasma samples were analysed for 233 metabolites using nuclear magnetic resonance (NMR) spectroscopy. Metabolomic signatures for UPF and MPF intake were derived using elastic net regression. Cox models examined associations between metabolomic signatures and incident CVD and T2D. Mediation analyses quantified the proportion explained by metabolomic signatures.</p> Results <p>We identified metabolomic signatures for UPF (34 metabolites) and MPF (50 metabolites). The UPF signature correlated positively with pro-inflammatory and atherogenic metabolites and inversely with omega-3 fatty acids and high-density lipoproteins; the MPF signature showed the opposite pattern. 1094 CVD and 853 T2D events occurred over 20 and 18 years median follow-up, respectively. Comparing the highest to lowest tertile, higher UPF signature scores were associated with greater risk of (hazard ratio [HR] = 1.19; 95% confidence interval [CI] 1.02–1.39) and T2D (HR = 1.20; 95% CI 1.03–1.42), whereas higher MPF signature scores were inversely associated with these outcomes (CVD: HR = 0.81; 95% CI 0.69–0.94; T2D: HR = 0.60; 95% CI 0.48–0.73). Associations between the signatures and outcomes were robust to additional adjustment for UPF or MPF intake. The signatures mediated 42.8–51.1% of processing-disease associations (51.1% for UPF-CVD, 46.6% for MPF-CVD, 42.8% for UPF-T2D, and 47.8% for MPF-T2D; all p &lt; 0.05).</p> Conclusions <p>Metabolomic signatures of UPF and MPF intake showed opposing associations with CVD and T2D risk, partially mediating these processing–disease associations. These findings suggest biological pathways linking UPF intake to adverse cardiometabolic outcomes, though the unexplained proportion indicates additional mechanisms may contribute.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating metabolomic signatures of ultra-processed and minimally processed food intake and risk of cardiovascular disease and type 2 diabetes: 20-year follow-up in the Whitehall II cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Mengmei E. Wang,
  • Annie Britton,
  • Michail Katsoulis,
  • Kiara Chang,
  • Eszter P. Vamos,
  • Clare H. Llewellyn

摘要

Background

Higher intakes of ultra-processed food (UPF) and minimally processed food (MPF) are linked to increased and decreased cardiometabolic risks, respectively, though mechanisms underlying these associations remain less understood. We aimed to identify metabolomic signatures associated with UPF and MPF intakes, examine their prospective associations with cardiovascular disease (CVD) and type 2 diabetes (T2D), and quantify their mediation of processing-disease associations.

Methods

In the Whitehall II cohort, UPF and MPF intakes in 6010 participants were derived using the Nova classification from 127-item food frequency questionnaires administered at phases 3 and 5 (1991–1994, 1997–1999), averaged across phases. Fasting plasma samples were analysed for 233 metabolites using nuclear magnetic resonance (NMR) spectroscopy. Metabolomic signatures for UPF and MPF intake were derived using elastic net regression. Cox models examined associations between metabolomic signatures and incident CVD and T2D. Mediation analyses quantified the proportion explained by metabolomic signatures.

Results

We identified metabolomic signatures for UPF (34 metabolites) and MPF (50 metabolites). The UPF signature correlated positively with pro-inflammatory and atherogenic metabolites and inversely with omega-3 fatty acids and high-density lipoproteins; the MPF signature showed the opposite pattern. 1094 CVD and 853 T2D events occurred over 20 and 18 years median follow-up, respectively. Comparing the highest to lowest tertile, higher UPF signature scores were associated with greater risk of (hazard ratio [HR] = 1.19; 95% confidence interval [CI] 1.02–1.39) and T2D (HR = 1.20; 95% CI 1.03–1.42), whereas higher MPF signature scores were inversely associated with these outcomes (CVD: HR = 0.81; 95% CI 0.69–0.94; T2D: HR = 0.60; 95% CI 0.48–0.73). Associations between the signatures and outcomes were robust to additional adjustment for UPF or MPF intake. The signatures mediated 42.8–51.1% of processing-disease associations (51.1% for UPF-CVD, 46.6% for MPF-CVD, 42.8% for UPF-T2D, and 47.8% for MPF-T2D; all p < 0.05).

Conclusions

Metabolomic signatures of UPF and MPF intake showed opposing associations with CVD and T2D risk, partially mediating these processing–disease associations. These findings suggest biological pathways linking UPF intake to adverse cardiometabolic outcomes, though the unexplained proportion indicates additional mechanisms may contribute.